272 KB17 KB199220251999Boyomo, Armand-BelebeineRadmard, AfshinWagner, Wolfgangštevilka:2letnik:33str. 153-157ISSN:1318-2099COBISSID_HOST:9974745URN:URN:NBN:SI:doc-S2Z7M1GRenCroatian Medical Association - Croatian Society of RadiologySlovenian Medical Society - Section of RadiologyRadiology and oncology (Ljubljana)Adverse effectsAmifostineDeglutition disordersDermatitisHead and neck neoplasmsNeoplasm stagingRadiation-protective agentsRadiotherapySialadenitisXerostomiaChemical radioprotection (WR-2721) in patients with head and neck cancer| Kemični radioprotektor (WR-2721) pri bolnikih s karcinomom glave in vratu|Background and methods. Amifostine was given as daily intravenous application (200mg/m2) 10-15 minutes prior to radiotherapy in 36 patients with locally advanced head and neck tumors to spare normal tissues, such as the salivary glands and oral cavity, from irradiation. Postoperative radiotherapy was carried out to a complete dose of 60 Gy given in 30 days, with single doses of2 Gy. Side effects of radiotherapy were assessed using the WHO-criteria. Results. According to the WHO-score, mucositis occurred in 10 patients (grade 1) and 26 patients (grade 2). Dysphagia was recorded in 10 patients as grade 1and in 12 patients as grade 2. Xerostomia was established as grade 1 in 14 patients and as grade 2 in 16 patients. Skin reactions were grade 1 in 9 patients and grade 2 in 13 patient. Drug related toxicity was recorded in 12 patients: hypotension grade 1 and nausea grade 2 were observed in 3 patients, while vomiting grade1 and grade 2 were documented in 3 and 1 patient respectively. Conclusions. According to the data from the literature, we believe that the application of amifostine is feasible, and amifostine is an effective radioprotector decreasing both acute and late side effects in patients irradiated for head and neck tumorsIzhodišča in metode. Da bi zaščitili zdravo tkivo ustne votline in žlez slinavk, smo 36 bolnikom z napredovalim rakom glave in vratu 10-15 minut pred obsevanjem intravensko injicirali 200mg/m2 amifostina. Bolnike smo postoperativno obsevali do skupne doze 60 Gy, z dozami po 2 Gy v 30 dneh. Stranske učinke radioterapije smo ovrednotili po merilih WHO. Rezultati.10 bolnikov je imelo mucositis 1. stopnje, 26 bolnikov pa mucositis 2. stopnje. Disfagijo 1. stopnje smo opazili pri 10 in 2. stopnje pri 12 bolnikih. Kožno reakcijo 1. stopnje smo zabeležili pri 9, 2.stopnje pa pri 13 bolnikih. Toksične sopojave amifostina smo opazili pri 12 bolnikih: hipotenzijo 1.stopnje in slabost 1. stopnje pri 3 bolnikih, bruhanje 1. stopnje pri 3, 2. stopnje pa pri 1 bolniku. Zaključki. Na osnovi naših podtakov in podatkov iz literature zaključujemo, da je uporaba amifostina kot radioprotektorja izvedljiva, in da amifostine ščiti zdrava tkiva pri obsevanju tumorjev glave in vratuTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaOnkološki inštitut Ljubljana